Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Gross Profit (2016 - 2025)

Historic Gross Profit for Heron Therapeutics (HRTX) over the last 10 years, with Q3 2025 value amounting to $26.3 million.

  • Heron Therapeutics' Gross Profit rose 1261.99% to $26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $114.6 million, marking a year-over-year increase of 1529.59%. This contributed to the annual value of $105.6 million for FY2024, which is 7055.01% up from last year.
  • Heron Therapeutics' Gross Profit amounted to $26.3 million in Q3 2025, which was up 1261.99% from $27.3 million recorded in Q2 2025.
  • Over the past 5 years, Heron Therapeutics' Gross Profit peaked at $30.6 million during Q4 2024, and registered a low of -$3.8 million during Q4 2021.
  • For the 5-year period, Heron Therapeutics' Gross Profit averaged around $15.0 million, with its median value being $13.2 million (2023).
  • As far as peak fluctuations go, Heron Therapeutics' Gross Profit tumbled by 13417.46% in 2021, and later surged by 3636000.0% in 2023.
  • Heron Therapeutics' Gross Profit (Quarter) stood at -$3.8 million in 2021, then soared by 554.1% to $17.4 million in 2022, then soared by 39.92% to $24.3 million in 2023, then increased by 25.48% to $30.6 million in 2024, then dropped by 13.92% to $26.3 million in 2025.
  • Its Gross Profit was $26.3 million in Q3 2025, compared to $27.3 million in Q2 2025 and $30.4 million in Q1 2025.